By Roshan Fernandez
Shares of Steris gained after the medical-device company beat analysts' expectations for its fourth-quarter per share results.
Shares climbed 5.5%, to $240, after hours Wednesday, and the stock is up about 11% since the beginning of the year.
The Dublin company reported a fiscal fourth-quarter profit of $145.7 million, or $1.48 a share, compared to a loss of $1.4 million, or 1 cent a share, a year earlier.
Excluding one-time items, per-share earnings were $2.74, beating analysts' expectations of $2.60, according to FactSet.
Revenue rose to $1.48 billion from $1.42 billion during the year-ago quarter. Analysts expected $1.47 billion.
That was driven in part by a rise in applied sterilization-technologies sales, which were up 9.2% compared to last year.
The company expects revenue for fiscal-year 2026 to increase 6% to 7%. That would be between about $5.79 billion to $5.84 billion, based on the $5.46 billion the company reported in revenue for fiscal-year 2025. That beats the $5.78 billion projected by analysts.
Adjusted earnings per share are expected to be between $9.90 and $10.15 for the fiscal year. Analysts were looking for $10 in adjusted per-share earnings.
Steris said its fiscal-year 2026 outlook includes an expected $30 million pre-tax hit to its profits as a result of tariffs.
Write to Roshan Fernandez at roshan.fernandez@wsj.com
(END) Dow Jones Newswires
May 14, 2025 17:59 ET (21:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.